NurExone Collaborates with Particle Metrix to Place NTA Instrument in Lab; Goal Is to Validate Methodology for Analysis of Loaded Exosomes in Development of Drug for Acute Spinal Cord Injury

On June 1, 2023, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, was pleased to announce a pioneering collaboration with the German company, Particle Metrix, a leading provider of particle analysis devices. In connection with the collaboration, a highly-advanced Nanoparticle Tracking Analysis ("NTA") instrument has been recently placed at NurExone’s laboratory, which is an important milestone in the expansion of NurExone’s production and analytic processes. The newly acquired NTA instrument, which is the first of its kind in Israel, is equipped with state-of-the-art capabilities including nanoparticle tracking analysis and advanced co-localization technology. The new system is a ZetaView TWIN Laser System PMX-230 using wavelengths of 520 and 640 nanometers for size, concentration, fluorescence, co-localization, and Zeta Potential analysis. As part of the collaboration, the two companies will share analytical data between each other in order to improve the co-localization performance of the device at these two wavelengths.

Login Or Register To Read Full Story